Sam Brusco, Associate Editor10.10.22
LimaCorporate has earned U.S. Food and Drug Administration (FDA) approval for its PRIMA shoulder platform.
The PRIMA shoulder’s glenoid baseplate and humeral stem are fully 3D-printed, a first for the company. The implant uses the firm’s Trabecular Titanium (TT) technology to encourage strong primary fixation and secondary bone growth.
A bone-preserving, fully convertible design facilitates simple exchange from anatomic to reverse configuration. Surgeons can move between baseplate designs to address different pathologies in a range of complexities.
"[This] FDA approval for PRIMA TT Glenoid represents an exciting opportunity to accelerate our market growth in key regions,” newly minted LimaCorporate CEO Massimo Calafiore told the press. “The new PRIMA shoulder platform will support our surgeons to bring the emotion of motion to even more patients!"
The PRIMA shoulder’s glenoid baseplate and humeral stem are fully 3D-printed, a first for the company. The implant uses the firm’s Trabecular Titanium (TT) technology to encourage strong primary fixation and secondary bone growth.
A bone-preserving, fully convertible design facilitates simple exchange from anatomic to reverse configuration. Surgeons can move between baseplate designs to address different pathologies in a range of complexities.
"[This] FDA approval for PRIMA TT Glenoid represents an exciting opportunity to accelerate our market growth in key regions,” newly minted LimaCorporate CEO Massimo Calafiore told the press. “The new PRIMA shoulder platform will support our surgeons to bring the emotion of motion to even more patients!"